Research ArticleOpen AccessGoogle Scholar indexed
Development and Validation of Stability Indicating Rapid RP-LC Method for Determination of Process and Degradation Related Impurities of Apremilast, an Anti-Inflammatory Drug
Department of Process Research and Development, Megafine Pharma (P) Ltd., Maharashtra, India
Department of Process Research and Development, Megafine Pharma (P) Ltd., Maharashtra, India
Department of Process Research and Development, Megafine Pharma (P) Ltd., Maharashtra, India
Department of Process Research and Development, Megafine Pharma (P) Ltd., Maharashtra, India
Department of Chemistry, Deogiri College, Aurangabad, India
Department of Process Research and Development, Megafine Pharma (P) Ltd., Maharashtra, India
- 1 Department of Process Research and Development, Megafine Pharma (P) Ltd., Maharashtra, India
- 2 Department of Process Research and Development, Megafine Pharma (P) Ltd., Maharashtra, India
- 3 Department of Process Research and Development, Megafine Pharma (P) Ltd., Maharashtra, India
- 4 Department of Process Research and Development, Megafine Pharma (P) Ltd., Maharashtra, India
- 5 Department of Chemistry, Deogiri College, Aurangabad, India
- 6 Department of Process Research and Development, Megafine Pharma (P) Ltd., Maharashtra, India
American Journal of Analytical Chemistry·Volume 08 (2017)·Pages 380–394·Published 12 June 2017·DOI10.4236/ajac.2017.86029
Copy link · social · email
Abstract
A new, specific, rapid and stability indicating reversed phase liquid chro-matographic (RP-LC) method for the determination of process related and degradation related impurities of Apremilast has been developed and validated. The degradation study performed in acid, base, oxidative, photolytic, and thermal stressed conditions. Eight process related impurities (Imp-1 to Imp-8) in test sample of Apremilast have been detected by developed RP-LC method. The good chromatographic resolution between the peaks of process related impurities, degradation impurities and Apremilast has been achieved on a Synergi Max-RP 80 A (150 × 4.6 mm ID), 4 μ column. The process and degradation related impurities were characterized by mass spectrometry, 1H NMR and FT-IR spectral data. The method was validated as per ICH guideline and found to be specific, rapid, and stability indicating. The proposed RP-PLC method was successfully applied to the analysis of drug substance samples of Apremilast.
KeywordsApremilastStability IndicatingRP-LCPDE4 InhibitorForced Degradation
- Schafer, P.H., Parton, A., Capone, L., Cedzik, D., Brady, H., Evans, J.F., Man, H.W., Stirling, D.I. and Chopra, R. (2014) Apremilast Is a Selective PDE4 Inhibitor with Regulatory Effects on Innate Immunity. Cellular Singalling, 26, 2016-2029. https://doi.org/10.1016/j.cellsig.2014.05.014
- Papp, K., Cather, J.C., Rosoph, L., Sofen, H., Langley, R.G., Matheson, R.T., Hu, C. and Day, R.M. (2012) Efficacy of Apremilast in the Treatment of Moderate to Severe Psoriasis: A Randomised Controlled Trial. Lancet, 380, 738-746. https://doi.org/10.1016/S0140-6736(12)60642-4
- Abdulrahim, H., Thistleton, S., Adebajo, A.O., Shaw, T. Edwards, C. and Wells, A. (2015) Apremilast: A PDE4 Inhibitor for the Treatment of Psoriatic Arthritis. Expert Opinion on Pharmacotherapy, 16, 1099-1108. https://doi.org/10.1517/14656566.2015.1034107
- Schafer, P.H., Parton, A., Gandhi, A.K., Capone, L., Adams, M., Wu, L., Bartlett, J.B., Loveland, M.A., Gilhar, A., Cheung, Y.-F., Baillie, G.S., Houslay, M.D., Man, H.-W., Muller, G.W. and Stirling, D.I. (2010) Apremilast, a cAMP Phosphodiesterase-4 Inhibitor, Demonstrates Anti-Inflammatory Activity in Vitro and in a Model of Psoriasis. British Journal of Pharmacology, 159, 842-855. https://doi.org/10.1111/j.1476-5381.2009.00559.x
- Gapone, L., Rogovitz, A., Gandhi, A.K. and Schafer, P.H. (2011) Arthritis Rheum, 63, 1844.
- Man, H.W., Schafer, P., Wong, L.M., Patterson, R.T., Corral, L.G., Raymon, H., Blease, K., Leisten, J., Shirley, M.A., Tang, Y., Babusis, D.M., Chen, R., Stirling, D. and Muller, G.W. (2009) Discovery of (S)-N-{2-[1-(3-Ethoxy-4-Methoxyphenyl)-2- Methanesulfonylethyl]-1,3-Dioxo-2,3-Dihydro-1H-Isoindol-4-yl}Acetamide (Apre- milast), a Potent and Orally Active Phosphodiesterase 4 and Tumor Necrosis Factor-α Inhibitor. Journal of Medicinal Chemistry, 52, 1522-1524. https://doi.org/10.1021/jm900210d
- Schafer, P.H. and Day, R.M. (2013) Novel Systemic Drugs for Psoriasis: Mechanism of Action for Apremilast, a Specific Inhibitor of PDE4. Journal of the American Academy of Dermatology, 68, 1041-1042. https://doi.org/10.1016/j.jaad.2012.10.064
- Gulen, H., Melike, M., Recep, T., Cengiz, K., Ozturk, T., Hasan, Y. and Yusuf, Y. (2015) Apremilast for Behcet’s Syndrome—A Phase 2, Placebo-Controlled Study. New England Journal of Medicine, 372, 1510. https://doi.org/10.1056/NEJMoa1408684
- http://www.ema.europa.eu/docs/en_GB/document_library/EPAR__Public_assessment_report/human/003746/WC500182629.pdf
- Chen, X.-L., Liu, Z.-Z. and Zhang, J. (2015) Determination of Apremilast in Rat Plasma by UPLC-MS/MS and Its Application to a Pharmacokinetic Study. Latin American Journal of Pharmacy, 34, 1417-1422.